

## Research Article

# VPS13D Mutations Affect Mitochondrial Homeostasis and Locomotion in *Caenorhabditis elegans*

Ruoxi Wang<sup>1,2</sup>, Andrea Thackeray<sup>3</sup>, Eric H. Baehrecke<sup>1</sup>, Mark J. Alkema<sup>3</sup>

1. Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, USA; 2. School of Life Sciences, Southern University of Science and Technology, China; 3. Department of Neurobiology, University of Massachusetts Chan Medical School, USA

Mitochondria control cellular metabolism, serve as hubs for signaling and organelle communication, and are important for the health and survival of cells. *VPS13D* encodes a cytoplasmic lipid transfer protein that regulates mitochondrial morphology, mitochondria and endoplasmic reticulum (ER) contact, quality control of mitochondria. *VPS13D* mutations have been reported in patients displaying ataxic and spastic gait disorders with variable age of onset. Here we used CRISPR/Cas9 gene editing to create *VPS13D* related-spinocerebellar ataxia-4 (SCAR4) missense mutations and C-terminal deletion in *VPS13D*'s orthologue *vps-13D* in *C. elegans*. Consistent with SCAR4 patient movement disorders and mitochondrial dysfunction, *vps-13D* mutant worms exhibit locomotion defects and abnormal mitochondrial morphology. Importantly, animals with a *vps-13D* deletion or a N3017I missense mutation exhibited an increase in mitochondrial unfolded protein response (UPR<sup>mt</sup>). The cellular and behavioral changes caused by *VPS13D* mutations in *C. elegans* advance the development of animal models that are needed to study SCAR4 pathogenesis.

**Corresponding authors:** Eric H. Baehrecke, [Eric.Baehrecke@umassmed.edu](mailto:Eric.Baehrecke@umassmed.edu); Mark J. Alkema, [mark.alkema@umassmed.edu](mailto:mark.alkema@umassmed.edu)

## Introduction

Mitochondria are dynamic organelles that play an important role in cellular bioenergetics and viability. The mitochondrial network undergoes continuous fusion and fission to maintain its health. In addition, mitochondria form dynamic contacts with other organelles, especially the endoplasmic reticulum, to

participate in various biological processes. Damaged mitochondria are selectively cleared by autophagy, and alterations in mitochondrial removal by autophagy have been associated with neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis<sup>[1]</sup>.

Vacuolar protein sorting-associated protein 13D, encoded by the *VPS13D* gene, is a key regulator of mitochondrial processes, including mitochondrial clearance, mitochondrial morphology, and inter-organelle contacts<sup>[2][3][4]</sup>. *VPS13D* is a member of the conserved VPS13 protein family, which facilitates membrane contacts and transport lipids between organelles<sup>[5]</sup>. Unlike the other three human VPS13 proteins (*VPS13A–C*), *VPS13D* possesses a unique ubiquitin-associated (UBA) domain that has been shown to interact with K63 ubiquitin chains and participate in mitochondrial health<sup>[2][5]</sup>. Mutations in the *VPS13A–C* genes have been linked to specific neurological disorders, including chorea-acanthocytosis, Cohen syndrome, and early-onset Parkinson's disease. Importantly, biallelic pathogenic variants in the *VPS13D* gene have also been associated with spastic ataxia and spastic paraplegia<sup>[6][7]</sup>.

*VPS13D* movement disorder, also referred to as autosomal recessive spinocerebellar ataxia-4 (*SCAR4*;<sup>[8]</sup> <sup>[6]</sup>), manifests as a hyperkinetic movement disorder characterized by dystonia, chorea, and/or ataxia. This disorder is often accompanied with varying degrees of developmental delay and cognitive impairment<sup>[9]</sup>. In the majority of the reported 42 cases, individuals have a combination of a loss-of-function variant and a seemingly milder variant, which can either be a missense mutation or a milder splicing variant<sup>[6][7][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]</sup>. Both *VPS13D*-deficient human and *Drosophila* cells exhibit notable abnormalities in mitochondrial morphology and clearance<sup>[6][2]</sup>. In addition, a genetic screen for altered mitochondria in *C. elegans* identified *C25H3.11* (*vps-13D*)<sup>[25]</sup>. Recent studies have linked *VPS13D* to Leigh syndrome<sup>[21][24]</sup> and the Parkinson's disease gene *PINK1*<sup>[26]</sup> suggesting that this gene has relevance to a broader spectrum of neurological diseases.

Strong loss-of-function *VPS13D* alleles are lethal in *Drosophila*<sup>[2]</sup> and mice<sup>[27]</sup>, thus presenting a challenge to model this disease in an intact animal. In this study, we used CRISPR/Cas9 gene editing techniques to create *SCAR4* patient-specific mutations in the *C. elegans* orthologue of the human *VPS13D* gene: *vps-13D*. We analyzed the effects of these *SCAR4* patient-specific mutations in *vps-13D* on worm fecundity, behavior, and mitochondrial morphology. We find that *vps-13D* deletion mutants display maternal effect sterility and locomotion defects. *vps-13D* deletions and the N3017I missense mutation displayed disrupted mitochondrial morphology and resulted in different degrees of activated mitochondrial unfolded protein

response (UPR<sup>mt</sup>). Furthermore, we identified a functional link between *vps-13D* and the mitochondria fusion regulator *fzo-1* in the same pathway to regulate mitochondrial dynamics and homeostasis. The combined biological changes caused by *VPS13D* mutations in *C. elegans* advance the development of a new animal model to study SCAR4 pathogenesis.

## Materials and methods

### *C. elegans* strains and GFP fusion construction

All *C. elegans* strains were maintained at 22°C on nematode growth medium (NGM) plates seeded with *Escherichia coli* OP50 bacteria. The wild-type strain was Bristol N2. Sterile mutant *vps-13D* strains were balanced with the *mIn1* balancer chromosome<sup>[28]</sup>. The *vps-13D* mutant strains were crossed with the following transgenes: *zCIs14* [*Pmyo-3::GFP (mit)*]<sup>[29]</sup>, *zCIs13* [*Phsp-6::GFP + lin-15 (+)*]<sup>[30][31]</sup>. A full list of strains used in this study is shown in Supplementary Table S1. The *Pvps-13D::GFP* transcriptional reporter was generated using the following primers: F(5'-ACAGGATCCTCGCATACAATCACATCGTC-3') and R(5'-ACAGGTACCTGTCCAGGAATTGTGGTATC-3'). These primers were used to amplify a 3.5 kb fragment corresponding to the upstream promoter sequence (including exon 1 and part of exon 2) of *vps-13D*. The PCR product was digested by BamHI and KpnI restriction enzymes and inserted into pPD95.75 vector. The *Pvps-13D::GFP* construct was microinjected at 50 ng/μl into temperature-sensitive *lin-15(n765ts)* mutant animals along with the *lin-15 (+)* rescuing plasmid (pL15EK) at 80 ng/μl and pBSK DNA at 80 ng/μl. Transgenics were selected at 22°C based on a non-Muv (Multivulva) phenotype and GFP fluorescence.

### CRISPR/Cas9 design and gene editing

The Bristol N2 strain was used as the wild-type strain for all CRISPR/Cas9 editing of *vps-13D*. Site-specific crRNAs and a repair template donor ssODNs were manually selected and generated by IDT (Integrated DNA Technologies, Inc.) who also provided the tracrRNA. Injection mixtures were prepared following established protocols<sup>[32]</sup> and *rol-6* was used as a co-CRISPR selection marker. All crRNAs, ssODNs, and PCR screening sequences are reported in Supplementary Table S2-S4. Correct substitution or deletion sequences were confirmed via Sanger sequencing. Sequencing of C-terminal deletion  $\Delta C$  (*zf197*) revealed a 1218-bp deletion (LGII 5670774–5671991) with a short 20-bp insertion positioned between the two breakpoints. The CRISPR-designed strains underwent four rounds of outcrossing to the N2 strain.

### *Brood size assay*

Ten L4 animals of each genotype were picked and separated onto individual plates. Animals were transferred onto new plates every day until the cessation of egg-laying. Plates were counted for the total number of eggs after removal of the parent animal.

### *Larval development analysis*

Five adult animals from each genotype were transferred to a new plate. After 2-hours, adult animals were removed, and the eggs were left to develop for over 96 hours. Two *vps-13D* deletion mutant strains were maintained as balanced heterozygotes using the *mIn1* [*dpy-10 (e128) mIs14*] balancer. This balancer includes an integrated pharyngeal GFP reporter expressed in a semi-dominant manner. Consequently, the offspring segregate into wild type with a dim GFP signal, Dpy with a bright GFP signal (*mIn1* homozygotes), and non-GFP *vps-13D* deletion homozygotes. For the *vps-13D* deletion strains only non-GFP homozygotes were evaluated at each developmental stage. The developmental timing was calculated as the proportion of larvae among the total number of hatched embryos that reached each specific developmental stage. The developmental stage of each individual was determined based on body size and stage-specific morphological features.

### *Multi-Worm Tracker assay*

10 synchronized 1-day old or 3-day old (24 hours or three days post the L4 stage) worms were placed on a thin lawn *E. coli* OP50 on a medium (5 cm) NGM plate. The plate was then placed in the Multi-Worm Tracker (MWT) (<https://sourceforge.net/projects/mwt/><sup>[33]</sup>) and recorded for 10 minutes. The Multi-Worm Tracker package includes real-time image analysis software and behavioral parameter measurement software, Choreography. Tracking and analysis were conducted following previous studies<sup>[34][35][36]</sup>. The average speed of the population was measured over 5 minutes after a 5-minute acclimation period. Experiments were analyzed using custom MATLAB (MathWorks, Inc.) scripts to interface with Choreography analysis program. The MATLAB scripts used in this study are available at [https://github.com/jeremyflorman/Tracker\\_GUI](https://github.com/jeremyflorman/Tracker_GUI). Analysis was limited to objects that had been tracked for a minimum of 20 seconds and had moved a minimum of 5 body lengths. For the analysis of single worm tracks, a plate containing a single 3-day old animal was recorded for 10 minutes with images captured every 2 seconds. The sequential images from the final 5 minutes post-acclimation were stitched and processed in ImageJ to generate a continuous worm movie track.

### *Thrashing assay*

10 age-synchronized young adult animals were transferred to a fresh unseeded plate to remove residual bacteria. Individual animals were subsequently transferred to M9 buffer in a tiny plate. After 15 seconds acclimatization, the number of completed thrashes during 1 minute were counted per animal using a hand counter.

### *Gene expression knockdown via RNAi treatment*

*fzo-1* RNAi bacteria clones, obtained from the Ahringer library<sup>[37]</sup>, were selected by ampicillin (100 mg/ml) and tetracycline (12.5 mg/ml) and verified by DNA sequencing. The control L4440 or *fzo-1* RNAi bacteria grown at 37°C overnight in LB with ampicillin (100 mg/ml), were concentrated (4X) and seeded on RNAi NGM plates that contain 6 mM IPTG and 100 mg/ml ampicillin. Young adult P0 animals were placed on the RNAi plates and allowed to produce offspring. L4 larvae of F1 progeny were transferred to a new RNAi plate. After two generations of RNAi-treatment, L4 larvae of F2 animals were analyzed.

### *Imaging and fluorescence quantification*

To assess the sterile phenotype, adult wild-type animals and *vps-13D* deletion mutant animals were placed on 2% agarose pads containing 60 mM sodium azide. Adult sterile animals were identified by the absence of embryos or oocytes in the uterus through DIC imaging using a Zeiss LSM 700 microscope. To explore the expression pattern of *vps-13D*, adult animals expressing a *Pvps-13D::GFP* reporter were mounted on 2% agarose pads containing 60 mM sodium azide. Images were captured using a Zeiss LSM 700 confocal microscope. To test the impact of *vps-13D* mutations on mitochondrial morphology, L4 animals expressing *zCIs14* transgene were mounted on 2% agarose pads containing 10 mM levamisole. Images were recorded using a Zeiss LSM 700 confocal microscope. For each genotype mitochondrial morphology in body wall muscles in the middle of the worm body was scored for 10~15 animals in total. To test the effects of *vps-13D* mutations on *hsp-6* expression of *C. elegans*, six L4 animals expressing *Phsp-6::GFP* grown on *E. coli* OP50 were mounted together on 2% agarose pads containing 10 mM levamisole and 18~36 animals in total. The GFP images were acquired with an Axioimager Z1 microscope (Zeiss) at 10x magnification, and the maximum fluorescence intensity was quantified using ImageJ FIJI software.

## *Mitochondrial morphology analysis*

Mitochondrial images were segmented and quantified using the Mitochondrial Segmentation Network (MitoSegNet) toolbox, a deep learning-based tool that includes the MitoS segmentation tool and the MitoA analysis tool<sup>[38]</sup>. Documentation for the MitoS and MitoA tools are available at <https://github.com/mitosegnet>, and the MitoSegNet segmentation model, along with the MitoA analysis and MitoS segmentation tools (GPU/CPU versions) for Linux and Windows, can be accessed at <https://zenodo.org/search?page=1&size=20&q=mitosegnet>. Initially, 8-bit raw images were segmented using the pretrained mitochondria-specific “basic mode” (MitoSegNet model) in the MitoS tool (CPU version). Upon completion, the program generated a prediction folder containing the segmented images. The segmented images and corresponding raw images were then subjected to quantitative measurement using the MitoA tool, which evaluates morphological features for each object and generates summary statistics for all object features in each image. The major axis lengths were determined by measuring the lengths of the line segment connecting the two vertices of an ellipse fitted around an object in the MitoA tool.

## *Statistical analysis*


All statistical analysis and graph construction were performed using GraphPad Prism 8 software. Results are presented as standard error of the mean (SEM) from at least three independent experiments. Statistical comparisons were performed using ANOVA or Kruskal-Wallis H test with Dunnett’s correction for multiple samples. Significance was determined when P-value < 0.05.

# **Results**

## *C. elegans vps-13D encodes an ortholog of VPS13D*

To explore the evolutionary relationships of the VPS13D proteins among various species, we first conducted a phylogenetic analysis. VPS13D proteins from different species formed a well-supported clade, indicating that they evolved from a common ancestor (Fig. 1A). The *C. elegans* C25H3.11 gene encodes a protein that shares the most significant similarity with VPS13D. The predicted Ricin B-type lectin domain-containing protein shares 36% similarity and 22% identity with the human VPS13D protein (Table S5). Furthermore, the highest sequence similarity between the two proteins was observed in the C-terminal region, which contains the VPS13 adaptor binding (VAB) domain<sup>[6]</sup> (also known as SHR

binding domain or WD40-like region<sup>[10]</sup>) and a Dbl homology (DH)-like domain (InterPro) (Fig. 1B). Given that *C25H3.11* gene is the closest *C. elegans* orthologue of the human *VPS13D* gene, we hereafter refer to *C25H3.11* as the *C. elegans vps-13D* gene. In humans, 14 of 30 reported families carry at least one missense mutation in the C-terminal region following the ubiquitin-associated (UBA) domain, and 5 of 8 reported homozygous missense mutations in patients are also located in this region<sup>[6][7][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]</sup>. Several of these mutation sites associated with human pathogenicity are highly conserved in the C-terminal region in *C. elegans* VPS13D protein (Fig. 1C).



**Figure 1. VPS13D orthologue *vps-13D* is conserved in *C. elegans*.** (A) Phylogenetic tree of VPS13D proteins. VPS13D protein sequences from various species were retrieved from UniProt. The evolutionary history was inferred using the neighbor-joining method. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches. Evolutionary analyses were conducted in MEGA11. The species depicted from top to bottom are Human (UniProt identifier: Q5THJ4), Bovine (UniProt identifier: E1BIF6), Mouse (UniProt identifier: B1ART2), Rat (UniProt identifier: A0A8I6G572), Zebrafish (UniProt identifier: A0A8M1QUR7), *Drosophila* (UniProt identifier: Q9VU08), *C. elegans* (labeled as brown diamond, UniProt identifier: A0A2K5ATR5) and Yeast (UniProt identifier: Q07878). (B) Human VPS13D protein topology (modified from [4]) and predicted domains of the *C. elegans* VPS-13D protein with disease-related missense mutations labeled in dotted vertical lines and deletions annotated with horizontal lines. Domains and abbreviations are as follows: N, Chorein N-terminal domain; Chorein domain; Extended Chorein domain; UBA, Ubiquitin-associated domain; VAB, Vps13 Adaptor Binding/SHR-Binding/WD40-like domain; Ricin B-type lectin domain; DH, Dbl homology-like domain; and PH, Pleckstrin homology domain. (C) Sequence alignment of C terminal region between *C. elegans* VPS-13D, human VPS13D, and fly Vps13D protein by Clustal Omega. The three missense mutations enrolled in this study are highlighted with the red box, and the start residue of *vps-13D* ( $\Delta C$ ) deletion is labeled with the red asterisk. (D) Representative fluorescence image of adult hermaphrodites expressing *Pvp13D::GFP* under the 3570bp



promoter (including exon 1 and part of exon 2). A, anterior; P, posterior; V, ventral side; D, dorsal side. The scale bar is 0.2 mm.

We next focused on three conserved residues within the C-terminal region of VPS13D protein that are reported to be mutated in early onset SCAR4 patients. We used CRISPR/Cas9 gene editing to create these variants in *vps-13D* (N2454S(zf194), N3017I(zf195) and R3144Q(zf196)) (Table 1). In addition, we generated a C-terminal deletion  $\Delta$ C(zf197) that encompassed 1218 base pairs, resulting in a truncation of the VPS13D protein (Fig. 1B). We also obtained a *vps-13D* deletion allele,  $\Delta$ (ok2632), which contains a 1740 bp deletion removing part of exons 3 and 4, resulting in a premature stop and thus most likely represents a null allele. To analyze the expression of *vps-13D*, we investigated its expression pattern by generating a transcriptional fusion of GFP reporter with 3.5kb *vps-13D* upstream promoter fragment (including exon 1 and part of exon 2).


<b><i>C. elegans</i> mutations (<i>vps-13D</i> a.1)</b>	<b><i>VPS13D</i> pathogenic mutations (NM_015378)</b>	<b>Clinical diagnosis of patients</b>	<b>Onset age</b>
N2454S (zf194)	p.N3521S (c.10562A>G)	Spastic ataxia with mild intellectual disability (2 patients)	2y/4-5y
N3017I (zf195)	p.N4107I (c. 12320A>T)	Ataxia, neuropathy, developmental delay, seizures, and optic atrophy	1y
R3144Q (zf196)	p.R4228Q (c.12683G>A)	Ataxia, muscle weakness, dystonia, mild intellectual disability	1-2y

**Table 1.** *VPS13D* pathogenic missense mutations in this study.

Fluorescence from the *Pvps-13D::GFP* reporter was observed throughout the adult hermaphrodite, including intestine, hypodermis, muscle, glia and neurons (Fig. 1D). Our data indicate that *vps-13D* is expressed in most cell types consistently with RNA expression data sets<sup>[39]</sup>.

### *vps-13D mutants exhibit impaired locomotion*

Animals carrying either homozygous *vps-13D* deletion alleles (*Δ(ok2632)* or *ΔC(zf197)*) are viable. However, both homozygous *vps-13D(Δ)* and *vps-13D(ΔC)* animals display maternal effect sterility (Fig. 2A). Wild-type hermaphrodites produce oocytes that are fertilized in the spermatheca, resulting in the accumulation of developing embryos in the uterus. The germlines of either homozygous *vps-13D(Δ)* or *vps-13D(ΔC)* animals did not display visible oocytes or embryos (Fig. 2B). Due to their sterility, these two deletion strains were maintained as balanced heterozygotes but analyzed as homozygotes by selecting homozygous animals from a mixed population. In addition to fertility deficiencies, these two deletion mutants also exhibited a slower rate of development, taking 24~48 hours longer than the wild type to reach the L4 stage (Fig. 2C). In contrast, three missense mutants *vps-13D(N2454S)*, (*N3017I*), and (*R3144Q*) did not exhibit developmental arrest or delay and were able to produce a similar brood size compared to the wild type (Fig. 2A).




**Figure 2. *vps-13D* deficiency affects worms' fertility and locomotion.** (A) Total brood size (n=30 broods) indicates the fertility ability of *C. elegans* to produce offspring in association with different *vps-13D* mutants. One-way ANOVA with Dunnett correction was used to compare the difference between wild-type and mutant animals. (B) DIC images of whole worm and gonad in hermaphrodites of the wild type and *vps-13D* ( $\Delta$ ) mutant strains. The scale bar in the whole worm image is 0.2 mm. The scale bar in the gonad image is 0.2  $\mu$ m. Black arrows indicate oocyte nuclei. (C) The percentage of worms at the different developmental stages was determined for wild-type, *vps-13D*( $\Delta$ ), and *vps-13D*( $\Delta$ C) mutant animals after 96 hours of growth from the embryonic stage at 22°C. (D) Individual animal tracks of 3-day-old wild type, *vps-13D*( $\Delta$ ) and *vps-13D*( $\Delta$ C) mutant strains for the final 5 min recordings. The scale bar is 1 mm. (E) Comparison of average velocity for 3-day-old wild-type and *vps-13D* animals from the final 5 mins MWT recordings. The velocity has been normalized and calculated based on the worm body lengths of respective strains. The difference in average velocity between wild-type and mutants was analyzed by one-way ANOVA with Dunnett's multiple comparison test. (F) Number of thrashes per minute in M9 liquid for 3-day-old wild type and *vps-13D* mutant animals (n=15-30). Differences between wild type and mutants were analyzed by One-way ANOVA with Dunnett correction for multiple comparisons.

Next, we examined whether *vps-13D* mutant strains possess motor defects. We conducted a population-level motility assay using an automated multi-worm tracking system (MWT)<sup>[33]</sup>. We tracked wild type and *vps-13D* mutant strains for 5 minutes and extracted the behavioral dynamics of individual worms. One-day-old adult *vps-13D* mutants did not show any difference compared to the wild-type (Fig. S1). However, *vps-13D* deletion animals displayed a noticeable movement impairment compared to wild-type animals. The average locomotion rate of 3-day-old wild-type animals was  $0.101 \pm 0.005$  body lengths/sec, whereas either *vps-13D(A)* or *vps-13D(AC)* mutants displayed decreased locomotion rates of  $0.064 \pm 0.010$  and  $0.065 \pm 0.012$  body lengths/sec (Fig. 2D-E). The three *vps-13D* missense mutant strain locomotion rates were unaffected at day 3 of the adult stage ( $0.111 \pm 0.009$ ,  $0.106 \pm 0.010$ ,  $0.099 \pm 0.008$  body lengths/sec, respectively, Fig. 2E). Furthermore, we analyzed thrashing rates of single worm in liquid M9 medium. The average thrashing rate of 3-day-old wild-type animals was  $113.2 \pm 6.9$  thrashes/min. Significantly, *vps-13D(A)* and *vps-13D(AC)* mutant strains showed a 20~26% decrease in thrashing rates compared to control wild-type animals ( $83.8 \pm 11.0$  thrashes/min,  $89.8 \pm 8.7$  thrashes/min, respectively, Fig. 2F). Importantly, the thrashing rate of *vps-13D(N3017I)* mutant worms was  $92.7 \pm 7.1$  thrashes/min, showing an 18% reduction compared to control animals (Fig. 2F), where *vps-13D(N2454S)* and *vps-13D(R3144Q)* mutants exhibited similar thrashing rates to the wild type ( $110.5 \pm 11.0$  thrashes/min,  $108.3 \pm 9.5$  thrashes/min, respectively). Combined, these results indicate that the *C. elegans vps-13D* mutations can result in locomotion defects.

### *vps-13D* mutants possess altered mitochondrial morphology

Dynamic changes in mitochondrial morphology are essential for mitochondria health and homeostasis. Mitochondrial fusion and fission not only affect mitochondria morphology but also regulate multiple mitochondria biological processes, including mitochondria quality control and clearance by mitophagy<sup>[40]</sup>. Previous studies indicate that VPS13D affects mitochondrial morphology and mitophagy in both human and *Drosophila* cells<sup>[2]</sup>. To test if *vps-13D* mutants exhibit a similar function to maintain mitochondrial morphology, we used a transgenic line *zcls14* ([*myo-3::GFP (mit)*]) that labels mitochondria in the body wall muscles<sup>[29]</sup> and quantified the mitochondrial morphology using MitoSegNet<sup>[38]</sup>. Although morphologies between different mutants were variable and possibly reflected allele strength, mutant strains of *vps-13D* displayed changes in mitochondrial morphology at the L4 larval stage compared to the wild type (Fig. 3A). Specifically, all homozygous *vps-13D* mutant worms possessed shorter mitochondria compared to control wild-type worms, as determined by the major axis length (Fig. 3A and 3B). In wild-type worms, the major axis length was  $31.4 \pm 11.6$  pixels. By contrast, *vps-13D(A)* and

*vps-13D(ΔC)* mutant strains displayed significantly reduced major axis lengths of  $18.1 \pm 3.7$  pixels and  $19.0 \pm 5.4$  pixels (Fig. 3B). Similarly, the major axis length was also reduced in the three *vps-13D* missense mutant strains, measuring  $19.7 \pm 5.7$ ,  $18.0 \pm 3.9$ ,  $22.3 \pm 9.5$  pixels, respectively (Fig. 3B). These data are consistent with a recent report<sup>[25]</sup>. In addition, both *vps-13D(Δ)* and *vps-13D(ΔC)* mutant strains demonstrated a notable increase in mitochondrial area measuring  $154.0 \pm 32.6$  pixels and  $144.7 \pm 30.2$  pixels, respectively, compared to  $113.5 \pm 19.6$  pixels in wild-type worms.




**Figure 3. *vps-13D* regulates mitochondrial morphology in *C. elegans*.** (A) Mitochondrial morphology of the wild type and *vps-13D* mutant animals. Original images are at the top and MitoSegNet segmentations are at the bottom. The scale bar is 20  $\mu$ m. (B, C) Statistical analysis of mitochondrial morphology parameters. Major axis length (see materials and methods) and average area were measured in segmented images of mitochondria from wild-type and *vps-13D* mutant animals (n=15–25). One-way ANOVA with Dunnett correction was used to compare the difference between wild-type and mutant animals. Data is presented as mean  $\pm$  S.E.M. \*p < 0.05, \*\*p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001, n.s. = not significant.

By contrast, *vps-13D(N2454S)* and *vps-13D(N3017I)* mutant strains display slightly smaller mitochondrial areas of  $86.5 \pm 20.9$  pixels and  $87.6 \pm 26.5$  pixels, respectively, where *vps-13D(R3144Q)* mutant is similar to the wild type ( $102.3 \pm 49.4$  pixels) (Fig. 3A and 3C). These results indicate that SCAR4 mutations in the *C. elegans* *VPS13D* ortholog *vps-13D* lead to alterations in mitochondrial morphology, supporting VPS-13D's role in maintaining mitochondrial structure.


### *vps-13D* disruption induces mitochondrial unfolded protein response

Although previous assays have examined the effects of *VPS13D* mutations on mitochondrial morphology, their impact on mitochondrial homeostasis remains unclear<sup>[2]</sup>. The mitochondrial unfolded protein response (UPR<sup>mt</sup>) is a crucial cellular pathway that protects mitochondria from multiple forms of cell stress<sup>[41]</sup>. To test whether *vps-13D* mutants affect UPR<sup>mt</sup>, we used a transgene of the transcriptional reporter *Phsp-6::mtHSP70::GFP* to monitor UPR<sup>mt</sup> in *C. elegans*<sup>[30][31]</sup>. Interestingly, *vps-13D(Δ)* and *vps-13D(ΔC)* mutant strains exhibit a significant induction of the UPR<sup>mt</sup> with high levels of *Phsp-6::mtHSP70::GFP* intensity compared to wild-type animals at L4 larval age (Fig. 4A and 4B). While the relative fluorescence intensity of *vps-13D(N2454S)* and *vps-13D(R3144Q)* missense mutants were not significantly different from wild type, homozygous *vps-13D(N3017I)* mutant worms exhibited a slight increase in UPR<sup>mt</sup> reporter expression compared to control worms (Fig. 4A and 4B). Combined, these results indicate that VPS13D plays a crucial role in maintaining mitochondrial homeostasis. Since the large deletion *Δ(ok2632)* allele, and the C-terminal deletion allele *ΔC (zf197)* causes similar deficiencies in fertility, development, locomotion, as well as mitochondrial morphology, we cannot exclude that frameshift mutations near the C-terminus could compromise protein stability.

A

*Phsp-6::GFP*

B




**Figure 4. *vps-13D* dysfunction induces mitochondrial UPR. (A)** *Phsp-6::GFP* expression of wild type and *vps-13D* mutant worms. The scale bar is 0.2 mm. **(B)** Quantification of *Phsp-6::GFP* relative fluorescence intensity (n=3–5 groups\*6 animals). Kruskal-Wallis H test with Dunnett correction was used to compare the difference between wild-type and mutant animals. Data is presented as mean ± S.E.M. \*p < 0.05, \*\*p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001, n.s. = not significant.

### *vps-13D* and *fzo-1/MFN2* function in a pathway to regulate mitochondrial homeostasis

In *Drosophila*, the orthologue of *MFN2*, *Marf* acts downstream of *Vps13D* to regulate mitochondrial fusion<sup>[3]</sup>. The *C. elegans* *MFN2* orthologue *FZO-1* is also involved in mitochondrial fusion<sup>[42]</sup>. Since our results indicate that *vps-13D* loss promotes alteration of mitochondrial morphology (Fig. 3), we examined the potential relationship between *VPS-13D* and *FZO-1* in the regulation of mitochondrial morphology. We performed RNA-mediated interference (RNAi) targeting *fzo-1* either in *vps-13D(Δ)* mutant background or in control worms. *fzo-1* knockdown worms exhibited a decrease in average major axis length ( $17.7 \pm 2.5$  pixels) and mitochondria area ( $77.8 \pm 8.5$  pixels) compared to control animals, which exhibited a major axis length of  $28.4 \pm 6.7$  pixels and a mitochondrial area of  $119.2 \pm 9.8$  pixels (Fig. 5A, 5B, and 5C). Knockdown of *fzo-1* failed to suppress the abnormal mitochondria morphology observed in *vps-13D(Δ)*

deficient animals (Fig. 5A, 5B, and 5C). The major axis length ( $20.6 \pm 6.5$  pixels) and mitochondria area ( $146.7 \pm 57.4$  pixels) of *vps-13D*( $\Delta$ ); *fzo-1*(RNAi) worms were similar to those observed in *vps-13D*( $\Delta$ ) control animals ( $19.4 \pm 4.2$  pixels in major axis length and  $157.4 \pm 40.1$  pixels in area). We also examined whether *fzo-1* affects mitochondria unfolded protein response (UPR<sup>mt</sup>). Consistent with previous studies<sup>[43]</sup>, the knockdown of *fzo-1* in wild-type worms led to a significant increase in the level of the UPR<sup>mt</sup> reporter *zcIs13* (Fig. 5D and 5E). However, *fzo-1* inactivation in *vps-13D*( $\Delta$ ) mutant worms did not result in a significant change in UPR<sup>mt</sup> compared to the *vps-13D*( $\Delta$ ) single mutant strain (Fig. 5D and 5E). Collectively, these data suggest that *vps-13D* and *fzo-1* function together to regulate mitochondria homeostasis.





**Figure 5. *vps-13D* and *fzo-1* regulate mitochondrial homeostasis in similar pathways.** (A) Mitochondrial morphology changes of wild type and *vps-13D(Δ)* animals grown on either control mock or *fzo-1 (RNAi)*. Original images are at the top and MitoSegNet model segmentations are at the bottom. The scale bar is 20  $\mu$ m. (B, C) Statistical analysis of mitochondrial morphology parameters. Major axis length (see materials and methods) and average area were measured in segmented images of mitochondria from wild type and *vps-13D(Δ)* animals grown on either control mock or *fzo-1 (RNAi)* (n=10-15). (D, E) *Phsp-6::GFP* expression of wild type and *vps-13D(Δ)* animals grown on either control mock or *fzo-1 (RNAi)* (n=3-15 groups\*6 animals). The scale bar is 0.2 mm. Kruskal-Wallis H test with Dunnett correction was used to compare the difference between wild-type and mutant animals. Data is presented as mean  $\pm$  S.E.M. \*p < 0.05, \*\*p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001, n.s. = not significant.

## Discussion

We developed a new model to study *VPS13D* related SCAR4 disease in the nematode *C. elegans*. Our results indicate that *C. elegans* carrying the *VPS13D* deletions and disease-associated missense mutations, in the worm orthologue *vps-13D*, are viable. However, *vps-13D* null deletion mutations that remove the C-terminal

display maternal effect sterility. In addition, *vps-13D* deletions and N3017I missense mutant *C. elegans* exhibit impaired locomotion, thus reflecting a similar role for this gene because human SCAR4 patients exhibit movement deficiencies. Importantly, *vps-13D* mutant *C. elegans* displayed abnormal mitochondrial morphology, and *vps-13D* deletions and *vps-13D(N3017I)* mutants displayed varying levels increased mitochondrial UPR.

The key clinical features of SCAR4 patients include progressive development of hyperkinetic movement disorder (dystonia, chorea, and/or ataxia). SCAR4 patient muscle biopsies exhibited mitochondrial accumulation and mild lipidosis<sup>[7]</sup>. Similarly, altered mitochondrial morphology and mitochondria clearance is decreased in cultured *VPS13D* patient-derived fibroblasts, *VPS13D* mutant human HeLa cells, and *Drosophila*<sup>[6][2][3]</sup>. Although mitochondrial respiratory chain function was normal in the muscle biopsy of one SCAR4 patient, a decrease in energy production and complex (I, III, and IV) protein levels has been detected in some patient fibroblasts<sup>[7][6][15]</sup>. Consistent with the movement defect of SCAR4 patients, worms carrying either deletions or N3017I missense mutations in *vps-13D* exhibited defects in crawling and/or swimming behavior. Interestingly, the abnormal swimming ability of *vps-13D* mutant worms is suggestive of mitochondrial dysfunction since swimming has been shown to be more energetically demanding than crawling for *C. elegans*<sup>[44][36]</sup>. The similarities between SCAR4 patients and *vps-13D* mutant worms, including locomotion defects, mitochondrial morphology, and mitochondrial homeostasis changes, suggest that *C. elegans* will likely be a useful model to reveal other genes in this pathway because of the strength of this genetic model.

Mitochondrial homeostasis is controlled by mitophagy machinery, including the PINK1-Parkin axis<sup>[45]</sup>. *VPS13D* functions downstream of PINK1, but bifurcates with Parkin to regulate mitochondrial clearance<sup>[26]</sup>. Specifically, *VPS13D* binds to ubiquitin and affects both the PINK1 substrate ubiquitinphospho-serine 65 and localization of the mitophagy receptor Ref2p/p62 on mitochondria<sup>[26]</sup>. Previous studies suggest mitophagy and mitochondrial UPR are both required to maintain mitochondrial health<sup>[46]</sup>. Mitophagy and mitochondrial UPR function in a complementary manner to either recycle the damaged mitochondria by autophagy or recover the less damaged mitochondria. Additionally, mitophagy inhibition also causes damaged mitochondrial DNA accumulation that triggers mitochondrial UPR. Recently, it has been shown that non-mitochondrial proteins, including *VPS13D*, also play a role in maintaining mitochondrial homeostasis<sup>[25]</sup>. Although it is unclear if *VPS13D* regulates mitochondria clearance in worms, evidence of *VPS13D* regulating mitophagy in different animals and human cells

suggest this possibility<sup>[2][26]</sup>. Therefore, *vps-13D* mutant worms may potentially accumulate damaged mitochondria to activate mitochondrial UPR.

Mitochondria and ER contact dictates inter-organelle lipid transfer sites and mitochondrial membrane lipid composition<sup>[47]</sup>. The lipid composition of mitochondrial membranes, in turn, can influence crucial processes within mitochondria<sup>[48][49]</sup>. Previous studies indicate Vmp1 and Vps13D regulate mitochondria-ER contact and mitophagy<sup>[3]</sup>. VPS13D binds the outer mitochondrial membrane GTPase-Miro (both Miro1 and Miro2), likely via the WD40-like/VAB domain<sup>[4]</sup>, and the conserved C-terminal regions have been shown to work synergistically with the VAB domain to facilitate the membrane targeting<sup>[50]</sup>. Moreover, the VPS13D C-terminus is similar to the lipid transfer protein ATG2<sup>[14]</sup>. Consistent with the importance of these domains, our data indicate that *vps-13D* C-terminus is important for mitochondrial homeostasis.

The mitochondrial protein mitofusin-2 (MFN2) facilitates mitochondrial fusion, as well as mitochondria and ER contact<sup>[51]</sup>. Mutations in *MFN2* are associated with Charcot-Marie-Tooth disease type 2A (CMT2A), in which mitochondrial morphology is abnormal in nerve tissue and fibroblasts from patients<sup>[52][53]</sup>. Similarly, loss of *fzo-1*, the worm *MFN2* homolog, resulted in progressive movement deficits, fragmented mitochondria, and mitochondrial UPR activation in *C.elegans*<sup>[54][55]</sup>. Consistent with these studies, our results indicate *fzo-1* knockdown worms displayed altered mitochondrial morphology and induced mitochondrial UPR. UPR<sup>mt</sup> activation requires the key transcription factor ATFS-1, which regulates the *hsp-6* reporter expression<sup>[56][57][58][59]</sup>. Notably, knockdown of *atfs-1* significantly suppressed UPR<sup>mt</sup> in the *fzo-1* mutant worms, confirming that UPR<sup>mt</sup> induction by loss of *fzo-1* is ATFS-1 dependent<sup>[60]</sup>. Unlike *Marf/MFN2* function in the Vps13D pathway regulating mitochondrial morphology in *Drosophila*<sup>[3]</sup>, our results suggest that *fzo-1* and *vps-13D* could function in a related pathway to affect mitochondrial UPR in *C. elegans*. In summary, this study provides evidence supporting the conserved role of VPS13D in regulating mitochondrial morphology and function in *C. elegans* and provides insights how disease mutations affect mitochondrial homeostasis and behavior.

## Additional information

**Figure S1. Day 1 *vps-13D* mutant worms did not show a significant deficiency in locomotion.** (A) Comparison of average velocity for 1-day-old young adult wild type and *vps-13D* mutant animals from the final 5 mins MWT recordings. The velocity has been normalized and calculated based on the worm body lengths of respective strains. The difference in average velocity between wild-type and mutants was

analyzed by one-way ANOVA with Dunnett's multiple comparison test. (B) Number of thrashes per minute in M9 liquid for 1-day-old young adult wild type and *vps-13D* mutant animals (n=10-15). Differences between wild type and mutants were analyzed by One-way ANOVA with Dunnett correction for multiple comparisons.

## Statements and Declarations

### *Funding*

This work was supported by National Institutes of Health grants R01 GM140480 (MJA) and R35 GM131689 (EHB).

### *Conflicts of interest*

The authors declare no conflict of interest.

### *Data availability*

All data files from this study have been uploaded to Mendeley Data (DOI: 10.17632/3mwgvd2dbx.1).

### *Acknowledgments*

We thank the Caenorhabditis Genetics Center (CGC), which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440), for some worm strains. We thank W.K. Kang, J.T. Florman, and M. Gorczyca for technical support and helpful discussions.

## References

1. <sup>a</sup>Collier JJ, Olahova M, McWilliams TG, Taylor RW (2023). "Mitochondrial signalling and homeostasis: from cell biology to neurological disease". *Trends Neurosci.* 46 (2): 137–152.
2. <sup>a, b, c, d, e, f, g, h</sup>Anding AL, Wang C, Chang TK, Sliter DA, Powers CM, et al. (2018). "Vps13D Encodes a Ubiquitin-Binding Protein that Is Required for the Regulation of Mitochondrial Size and Clearance". *Curr Biol.* 28 (2): 287–295 e286.
3. <sup>a, b, c, d, e</sup>Shen JL, Fortier TM, Zhao YG, Wang R, Burmeister M, et al. (2021b). "Vmp1, Vps13D, and Marf/Mfn2 function in a conserved pathway to regulate mitochondria and ER contact in development and disease". *Current Biology.* 31 (14): 3028–3039 e3027.

4. <sup>a, b, c</sup>Guillen-Samander A, Leonzino M, Hanna MG, Tang N, Shen H, et al. (2021). "VPS13D bridges the ER to mitochondria and peroxisomes via Miro". *J Cell Biol.* 220 (5).
5. <sup>a, b</sup>Leonzino M, Reinisch KM, De Camilli P (2021). "Insights into VPS13 properties and function reveal a new mechanism of eukaryotic lipid transport". *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.* 1866 (10): 159003.
6. <sup>a, b, c, d, e, f, g, h</sup>Seong E, Insolera R, Dulovic M, Kamsteeg EJ, Trinh J, et al. (2018). "Mutations in VPS13D lead to a new recessive ataxia with spasticity and mitochondrial defects". *Annals of Neurology.* 83 (6): 1075–1088.
7. <sup>a, b, c, d, e</sup>Gauthier J, Meijer IA, Lessel D, Mencacci NE, Krainc D, et al. (2018). "Recessive mutations in VPS13D cause childhood onset movement disorders". *Ann Neurol.* 83 (6): 1089–1095.
8. <sup>A</sup>Swartz BE, Burmeister M, Somers JT, Rottach KG, Bespalova IN, et al. (2002). "A form of inherited cerebellar ataxia with saccadic intrusions, increased saccadic speed, sensory neuropathy, and myoclonus". *Annals of the New York Academy of Sciences.* 956: 441–444.
9. <sup>A</sup>Meijer IA (2019). "VPS13D Movement Disorder in GeneReviews®), edited by M.P. Adam, G.M. Mirzaa, R.A. Pagon, S.E. Wallace, L.J.H. Bean, et al. University of Washington, Seattle Copyright © 1993–2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., Seattle (WA)."
10. <sup>a, b, c</sup>Koh K, Ishiura H, Shimazaki H, Tsutsumiuchi M, Ichinose Y, et al. (2020). "VPS13D-related disorders presenting as a pure and complicated form of hereditary spastic paraplegia". *Mol Genet Genomic Med.* 8 (3): e1108.
11. <sup>a, b</sup>Petry-Schmelzer JN, Keller N, Karakaya M, Wirth B, Fink GR, et al. (2021). "VPS13D: One Family, Same Mutations, Two Phenotypes". *Movement Disorders Clinical Practice.* 8 (5): 803–806.
12. <sup>a, b</sup>Wang Yu WS, Cheng Yun, Song Bin, Jin Ping, Zhu Yulong, Sun Dandan, Ai Wenlong, Fu Xiaoming, Ye Qunrong, Li Kai, Wang Xun (2021). "A case report of complex heterozygous VPS13D mutation with spinocerebellar ataxia recessive type 4". *Chinese Medical Case Repository.* 03 (01): E211–E211.
13. <sup>a, b</sup>Huang X, Fan DS (2022). "Autosomal recessive spinocerebellar ataxia type 4 with a VPS13D mutation: A case report". *World J Clin Cases.* 10 (2): 703–708.
14. <sup>a, b, c</sup>Oztop-Cakmak O, Simsir G, Tekgul S, Aygun MS, Gokler O, et al. (2022). "VPS13D-based disease: Expansion of the clinical phenotype in two brothers and mutation diversity in the Turkish population". *Revue Neurologique (Paris).* 178 (9): 907–913.
15. <sup>a, b, c</sup>Durand CM, Angelini C, Michaud V, Delleci C, Couprie I, et al. (2022). "Whole-exome sequencing confirms implication of VPS13D as a potential cause of progressive spastic ataxia". *BMC Neurol.* 22 (1): 53.

16. <sup>a</sup> <sup>b</sup>Pauly MG, Bruggemann N, Efthymiou S, Grozinger A, Diaw SH, et al. (2023). "Not to Miss: Intronic Variants, Treatment, and Review of the Phenotypic Spectrum in VPS13D-Related Disorder". *International Journal of Molecular Sciences*. 24 (3).
17. <sup>a</sup> <sup>b</sup>Baker EK, Han J, Langley WA, Reott MA Jr, Hallinan BE, et al. (2023). "RNA sequencing reveals a complete picture of a homozygous missense variant in a patient with VPS13D movement disorder: a case report and review of the literature". *Mol Genet Genomics*. 298 (5): 1185–1199.
18. <sup>a</sup> <sup>b</sup>Harada S, Azuma Y, Misumi Y, Hayashi H, Matsubara S, et al. (2024). "A Novel Mutation of VPS13D-related Disorders with Parkinsonism". *Intern Med*.
19. <sup>a</sup> <sup>b</sup>Sultan T, Scorrano G, Panciroli M, Christoforou M, Raza Alvi J, et al. (2024). "Clinical and molecular heterogeneity of VPS13D-related neurodevelopmental and movement disorders". *Gene*. 899: 148119.
20. <sup>a</sup> <sup>b</sup>Nordli DR, 3rd, Galan FN (2023). "Progressive basal ganglia damage and EE-SWAS in a patient with a VPS13D pathogenic variant". *Epileptic Disorders*. 25 (1): 117–119.
21. <sup>a</sup> <sup>b</sup> <sup>c</sup>Kistol D, Tsygankova P, Krylova T, Bychkov I, Itkis Y, et al. (2023). "Leigh Syndrome: Spectrum of Molecular Defects and Clinical Features in Russia". *Int J Mol Sci*. 24 (2).
22. <sup>a</sup> <sup>b</sup>Kistol D, Tsygankova P, Bostanova F, Orlova M, Zakharova E (2024). "New Case of Spinocerebellar Ataxia 4, Autosomal Recessive 4, Due to VPS13D Variants". *Int J Mol Sci*. 25 (10).
23. <sup>a</sup> <sup>b</sup>Algahtani H, Shirah B, Naseer MI (2024). "Autosomal recessive spinocerebellar ataxia type 4 due to a novel homozygous mutation in the VPS13D gene in a Saudi family". *Clin Neurol Neurosurg*. 240: 108271.
24. <sup>a</sup> <sup>b</sup> <sup>c</sup>Lee JS, Yoo T, Lee M, Lee Y, Jeon E, et al. (2020). "Genetic heterogeneity in Leigh syndrome: Highlighting treatable and novel genetic causes". *Clinical Genetics*. 97 (4): 586–594.
25. <sup>a</sup> <sup>b</sup> <sup>c</sup>Rolland S, Conrad B (2022). "Genetic screen identifies non-mitochondrial proteins involved in the maintenance of mitochondrial homeostasis". *MicroPublication Biology*. 2022.
26. <sup>a</sup> <sup>b</sup> <sup>c</sup>Shen JL, Fortier TM, Wang R, Baehrecke EH (2021a). "Vps13D functions in a Pink1-dependent and Parkin-independent mitophagy pathway". *Journal of Cell Biology*. 220 (11).
27. <sup>a</sup>Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, et al. (2011). "A conditional knockout resource for the genome-wide study of mouse gene function". *Nature*. 474 (7351): 337–342.
28. <sup>a</sup>Edgley ML, Riddle DL (2001). "LG II balancer chromosomes in *Caenorhabditis elegans*: mT1(II;III) and the mIn1 set of dominantly and recessively marked inversions". *Mol Genet Genomics*. 266 (3): 385–395.
29. <sup>a</sup> <sup>b</sup>Benedetti C, Haynes CM, Yang Y, Harding HP, Ron D (2006). "Ubiquitin-like protein 5 positively regulates chaperone gene expression in the mitochondrial unfolded protein response". *Genetics*. 174 (1): 229–239.

30. <sup>a</sup>Yoneda T, Benedetti C, Urano F, Clark SG, Harding HP, et al. (2004). "Compartment-specific perturbation of protein handling activates genes encoding mitochondrial chaperones". *Journal of Cell Science*. 117 (Pt 18): 4055–4066.
31. <sup>a</sup>Yang Q, Liu P, Anderson NS, Shpilka T, Du Y, et al. (2022). "LONP-1 and ATFS-1 sustain deleterious hetero plasmidy by promoting mtDNA replication in dysfunctional mitochondria". *Nature Cell Biology*. 24 (2): 181–193.
32. <sup>Δ</sup>Ghanta KS, Ishidate T, Mello CC (2021). "Microinjection for precision genome editing in *Caenorhabditis elegans*". *STAR Protoc*. 2 (3): 100748.
33. <sup>a</sup>Swierczek NA, Giles AC, Rankin CH, Kerr RA (2011). "High-throughput behavioral analysis in *C. elegans*". *Nature Methods*. 8 (7): 592–598.
34. <sup>Δ</sup>Huang YC, Pirri JK, Rayes D, Gao S, Mulcahy B, et al. (2019). "Gain-of-function mutations in the UNC-2/CaV 2alpha channel lead to excitation-dominant synaptic transmission in *Caenorhabditis elegans*". *Elife*. 8.
35. <sup>Δ</sup>Florman JT, Alkema MJ (2022). "Co-transmission of neuropeptides and monoamines choreograph the *C. elegans* escape response". *PLoS Genet*. 18 (3): e1010091.
36. <sup>a</sup>Kang WK, Florman JT, Araya A, Fox BW, Thackeray A, et al. (2024). "Vitamin B(12) produced by gut bacteria modulates cholinergic signalling". *Nat Cell Biol*. 26 (1): 72–85.
37. <sup>Δ</sup>Kamath RS, Ahringer J (2003). "Genome-wide RNAi screening in *Caenorhabditis elegans*". *Methods*. 30 (4): 313–321.
38. <sup>a</sup>Fischer CA, Besora-Casals L, Rolland SG, Haeussler S, Singh K, et al. (2020). "MitoSegNet: Easy-to-use Deep Learning Segmentation for Analyzing Mitochondrial Morphology". *iScience*. 23 (10): 101601.
39. <sup>Δ</sup>Taylor SR, Santpere G, Weinreb A, Barrett A, Reilly MB, et al. (2021). "Molecular topography of an entire nervous system". *Cell*. 184 (16): 4329–4347 e4323.
40. <sup>Δ</sup>Pickles S, Vigie P, Youle RJ (2018). "Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance". *Current Biology*. 28 (4): R170–R185.
41. <sup>Δ</sup>Shpilka T, Haynes CM (2018). "The mitochondrial UPR: mechanisms, physiological functions and implications in ageing". *Nature Reviews Molecular Cell Biology*. 19 (2): 109–120.
42. <sup>Δ</sup>Rolland SG, Lu Y, David CN, Conradt B (2009). "The BCL-2-like protein CED-9 of *C. elegans* promotes FZO-1/Mfn1,2- and EAT-3/Opa1-dependent mitochondrial fusion". *Journal of Cell Biology*. 186 (4): 525–540.
43. <sup>Δ</sup>Haeussler S, Kohler F, Witting M, Premm MF, Rolland SG, et al. (2020). "Autophagy compensates for defects in mitochondrial dynamics". *PLoS Genet*. 16 (3): e1008638.

44. <sup>△</sup>Laranjeiro R, Harinath G, Burke D, Braeckman BP, Driscoll M (2017). "Single swim sessions in *C. elegans* induce key features of mammalian exercise". *BMC Biology*. 15 (1): 30.
45. <sup>△</sup>Pickrell AM, Youle RJ (2015). "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease". *Neuron*. 85 (2): 257–273.
46. <sup>△</sup>Pellegrino MW, Haynes CM (2015). "Mitophagy and the mitochondrial unfolded protein response in neurodegeneration and bacterial infection". *BMC Biology*. 13: 22.
47. <sup>△</sup>Gatta AT, Levine TP (2017). "Piecing Together the Patchwork of Contact Sites". *Trends Cell Biol*. 27 (3): 214–229.
48. <sup>△</sup>Bockler S, Westermann B (2014). "Mitochondrial ER contacts are crucial for mitophagy in yeast". *Dev Cell*. 28 (4): 450–458.
49. <sup>△</sup>Lahiri S, Toulmay A, Prinz WA (2015). "Membrane contact sites, gateways for lipid homeostasis". *Curr Opin Cell Biol*. 33: 82–87.
50. <sup>△</sup>Dziurdzik SK, Conibear E (2021). "The Vps13 Family of Lipid Transporters and Its Role at Membrane Contact Sites". *Int J Mol Sci*. 22 (6).
51. <sup>△</sup>Filadi R, Pendin D, Pizzo P (2018). "Mitofusin 2: from functions to disease". *Cell Death Dis*. 9 (3): 330.
52. <sup>△</sup>Verhoeven K, Claeys KG, Zuchner S, Schroder JM, Weis J, et al. (2006). "MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2". *Brain*. 129 (Pt 8): 2093–2102.
53. <sup>△</sup>Amiott EA, Lott P, Soto J, Kang PB, McCaffery JM, et al. (2008). "Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations". *Exp Neurol*. 211 (1): 115–127.
54. <sup>△</sup>Byrne JJ, Soh MS, Chandhok G, Vijayaraghavan T, Teoh JS, et al. (2019). "Disruption of mitochondrial dynamics affects behaviour and lifespan in *Caenorhabditis elegans*". *Cell Mol Life Sci*. 76 (10): 1967–1985.
55. <sup>△</sup>Haeussler S, Yeroslaviz A, Rolland SG, Luehr S, Lambie EJ, et al. (2021). "Genome-wide RNAi screen for regulators of UPR<sub>mt</sub> in *Caenorhabditis elegans* mutants with defects in mitochondrial fusion". *G3 (Bethesda)*. 11 (7).
56. <sup>△</sup>Lin YF, Schulz AM, Pellegrino MW, Lu Y, Shaham S, et al. (2016). "Maintenance and propagation of a deleterious mitochondrial genome by the mitochondrial unfolded protein response". *Nature*. 533 (7603): 416–419.
57. <sup>△</sup>Xin N, Durieux J, Yang C, Wolff S, Kim HE, et al. (2022). "The UPR<sub>mt</sub> preserves mitochondrial import to extend lifespan". *Journal of Cell Biology*. 221 (7).
58. <sup>△</sup>Shpilka T, Du Y, Yang Q, Melber A, Uma Naresh N, et al. (2021). "UPR<sub>(mt)</sub> scales mitochondrial network expansion with protein synthesis via mitochondrial import in *Caenorhabditis elegans*". *Nature Communications*. 12 (1): 479.



59. <sup>Δ</sup>Nargund AM, Fiorese CJ, Pellegrino MW, Deng P, Haynes CM (2015). "Mitochondrial and nuclear accumulation of the transcription factor ATFS-1 promotes OXPHOS recovery during the UPR(mt)". *Molecular Cell*. 58 (1): 123–133.
60. <sup>Δ</sup>Chen LT, Lin CT, Lin LY, Hsu JM, Wu YC, et al. (2021). "Neuronal mitochondrial dynamics coordinate systemic mitochondrial morphology and stress response to confer pathogen resistance in *C. elegans*". *Dev Cell*. 56 (12): 1770–1785 e1712.

## Declarations

**Funding:** No specific funding was received for this work.

**Potential competing interests:** No potential competing interests to declare.